CYAD
$6.81
Celyad Sa Ads
($.16)
(2.30%)
CYAD
Earnings Whisper ®
N/A
1st Quarter March 2021
Consensus:  $0.00
Revenue:  N/A
Wednesday
Mar 24
After the close
Score
Grade
Tweet Share Watch
Tweet Share Watch
Latest EPS

What do you expect when CYAD reports earnings?
Beat
Meet
Miss

Where is CYAD's stock price going from here?
Up
Flat
Down
Stock chart of CYAD
Analysts
Summary of analysts' recommendations for CYAD
Score
Grade
Pivots
Resistance
-
-
-

-

Support
-
-
-
Tweet
Growth
Description
Celyad SA is a biopharmaceutical company. The Company develops and commercializes cell based regenerative therapies to treat illnesses where cardiac tissue is lost due to chronic or acute injury. Celyad SA is based in Mont-Saint-Guibert, Belgium.